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Cardiac Changes at Autopsy in Adult Liver Transplant Recipients 
Under Tacrolimus 
A. Khanna, A. Jain, G. Ziady, A.J. Demetris, J.J. Fung, D. Kramer, and T.E. Starzl 
TACROLIMUS (FK506) is being used as immunosup-pressant in solid organ transplantation. However, its 
nephrotoxic and neurotoxic effects are well recognized. 
Recently reversible hypertrophic cardiomyopathy under 
tacrolimus has been described in five children. 1 In order to 
evaluate myocardial toxicity of the drug. we examined the 
cardiac findings at autopsy in adults and children following 
primary liver transplantation (OLTx) under tacrolimus and 
compared them with autopsy findings of patients who died 
of end-stage liver disease without OLTx and tacrolimus. 
MATERIALS AND METHODS 
Patients who received OL Tx between August 1989 and December 
1<)92 (834 adults. age> 18 years) were followed through April 1995. 
Sixty-seven (2<)%) of 228 patients who died during the follow-up 
period underwent autopsy (study group). Cardiac findings at 
autopsy were compared with 72 adults who died of end-stage liver 
disease without OL Tx and Tacrolimus (control group). The param-
eters studied were weight of the heart. left (LV) and right (RV) 
ventricular wall thickness. circumferences of tricuspid (TV). pul-
monary (PV). mitral (MV). and aortic (A V) valves. and macro-
scopic and microscopic appearances of the cardiac musculature. 
The prescnce of associated problems of hypertension. coronary 
artery disease. and infective endocarditis was taken into account. 
A\I hearts were subjected to formalin fixation for 12 to 24 hours 
followed hy cutting according to "flow of hlood method. "2 
DEMOGRAPHICS 
Mean age in the study group (51.3 :::: !3 years) and the control 
group (52.5 = 13.7 years) were comparahle. There were more 
maks in the study group (M = -l-l. F = 23) compared to the control 
group (M .\9. F = 33). The mean period of exposure to 
tacrolimus in the study group was h.I :::: S.C! months. 
RESULTS 
Mean weight of the heart. wall thickness of both ventricles, 
and circumference of all valves are shown in Table 1. The 
mean weight of the heart in both the groups is comparable 
(458:!: 105 g study group and 470 :!: 109.5 g control group). 
The average weight of the heart in both groups was 
increased as compared to normal popUlation (275 ± 75 g). 
None of the patients in either group had had any congenital 
or acquired valvular abnormality. 
Mean R V wall thickness in both the groups were com-
parable and normal (RV = 0.47 :!: 0.2 em study group. 
0.5 ± 0.2 cm control group, 0.4 to 0.5 em normal popula-
tion). Mean LV wall thickness. however. was increased in 
both groups as compared to the normal population (LV = 
1.65 :!: 0.4 cm study group. 1.6 :!: 0.3 cm control group, 0.8 
to 1.5 em normal population). Table 2 shows left ventricle 
wall thickness in both groups of patients. The circumfer-
ences of valves were comparable as shown in Table 1. Mean 
TV circumference 12 :!: 1.3 em in the study group as 
compared to 12 :!: 1.2 cm in the control group, PV 8.1 ± 1.1 
cm compared to 8.1 :!: 1.1 em in control group, the 
corresponding numbers for MV and A V being 10.5 :!: 1.3 
cm against 10 :!: 1.2 cm. and 7.7 :!: 1.2 cm against 7.4 :!: 0.9 
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Table 1. Cardiac Changes at Autopsy in Adult Liver Transplant Recipients Under Tacrolimus 
Study Group (A) N 67 
Wall thickness Valve Circumference 
Weight 
Igi RV LV rv PV MV AV 
Mean -158 0.47 1.65 12 8.1 10.5 77 
SD 105 0.2 0.4 1.3 11 1.3 i .2 
Median .\40 0.4 1.55 12 8 10.5 ?6 
RV rloht ventrtCle: LV left ventncle: TV tncusplc valve: PV pulmonary valve; 
0041-1315/97/$17.00 
PII S0041-1345(96)00254-0 
532 
MV 
Control Group (S) N 72 
Wall 
thickness Valve Circumference 
Weight 
(g) RV LV TV PV MV AV 
470.2 0.5 16 12 8 10 (-1 
109.5 0.2 0.3 1.2 1.1 1.2 0.9 
460 0.4 1.6 12 8 10 7.5 
mitral valve: AV aortiC valve. 
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Table 2. 
Group (A) 
n (%) 
11 (18) 
38 (63) 
11 (18) 
LV Wall Thickness 
Group (6) 
n(%) 
13 (18) 
42 (61) 
15 (20) 
cm. respectively. These are normal when compared with the 
dimensions in normal population. TV = 10 to 12.5 cm. 
PV = 7 to 9 cm. MV = 8 to 10.5 cm and AV = 8 to 10 cm. 
The incidence of myocardial infarction. coronary artery 
disease and. infective endocarditis was noted to be 12%. 
45%. and 16% in the study group and 8o/r. 58%. and 4% in 
the control group. respectively. 
DISCUSSION 
Liver failure and chronic liver disease are associated with 
peripheral vasodilatation and increased cardiac output he-
modynamic changes which affect the myocardium causing 
hypertrophy. This has been well established and also con-
firmed in a series by Park et al:' They based their study on 
echocardiography findings in 73 liver failure patients before 
and after liver transplantation and confirmed that there is a 
tendency to myocardial hypertrophy. chamber enlargement. 
and increased cardiac output in patients with chronic liver 
disease. Echocardiography on these patients performed at 5 
weeks to 15 months posttransplant showed reduction in LV 
end diastolic dimensions in all except one (P < .2). There 
was also a reduction in stroke volume index from 53 mLlm2 
to 34 mLim2 and in mean cardiac index from 5.S Llmin/m 2 
to 3.11 Limin/m 2 after OL Tx (P < .00 I). 
In our study. an increase in weight of heart and LV 
thickness were comparable in ooth the groups. This could 
be uue to a number of reasons. Liver failure. t'luiu status. 
repeat blood transfusions. and steroid therapy j contribute 
to a hyperdvnamic state that can cause mYOl.:ardial hyper-
trophy. It would have been helpful if we had pre- and 
posttransplant echocaruiograms in the study anu control 
population. This woulu have helpeu us compare these with 
~lutopsy uimensillns. 
Assm;iated renal uysfunction. hypertension. and infusions 
of colloids (intravcnous albumin and packed cell transfu-
sion) would alkc! the hemodynamic status and c(lulu 
contrlhute to the development of cardiac hvpertrophy. The 
illlpnllcment rcportcd hy ,\tkinson ct all ill P:ltiCllt, with 
l'ardiolllvopathv aftcr withdrawal of q~lcrolimus mav have 
hl'cn attributable III part til these ilctor~K yticrll~iDopic 
c\;lllllllalillll 01 Ihc IIlHll'arlilUlll l'onlirmed the prc'l'I1L'c 01 
hypertrophy in our patients. Cardiotoxic side effects have 
not been reported in the cxperimental toxicologic evalua-
tion of FK 506 in rats. dogs. and baboons.5 Tacrolimus in 
high doses (0.4 mg/kg IV q d) has been known to cause 
myocardial necrosis in rabbits. This is reversible upon 
stopping the drug. h However. this experimental study did 
not show any evidence of hypertrophic cardiomyopathy 
induced by Tacrolimus. 
CONCLUSION 
Liver failure is associated with cardiac changes that essen-
tially include myocardial hypertrophy and increase in heart 
weight and dimensions. namely thickness of ventricles and 
circumferences of valves. The effect is related to hemody-
namic changes accompanying liver failure. OLTx amelio-
rates the hyperdynamic state. thus improving the hemody-
namic status which may cause regression of cardiac 
dimensions (repeat echoeardiograms after 3 months). Car-
diac hypertrophy. however. may persist after liver trans-
plantation due to augmentation effect of steroids these 
patients routinely receive and failure of portosystemic 
shunts to close. It would be naive attribute these changes to 
a specific therapeutic agent. 
This study confirms that cardiac findings at autopsy in 
primary OL Tx recipients treated with Tacrolimus and pa-
tients with end-stage liver disease without OL Tx and Ta-
crolimus arc comparable for weight of the heart. wall 
thickness. valve circumference. and evidence of myocardial 
infarction. The rate of infective endocarditis was higher in 
the study group. The rate of coronary artery disease was 
higher in the control group. Left ventricle hypertrophy was 
found in X07r of the patients in both groups and is due to 
liver failure and hemodynamic changes associated with it 
rather than a direct dfect of drug therapy. 
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